www.obroncology.com
Open in
urlscan Pro
76.76.21.164
Public Scan
Submitted URL: http://obroncology.com/
Effective URL: https://www.obroncology.com/
Submission Tags: tranco_l324
Submission: On March 29 via api from DE — Scanned from DE
Effective URL: https://www.obroncology.com/
Submission Tags: tranco_l324
Submission: On March 29 via api from DE — Scanned from DE
Form analysis 1 forms found in the DOM
<form id="nav-search-form-id"></form>Text Content
* Cancer Types * Cancer Types * Conferences * Conferences * Expert Insights * Expert Insights * Business & Policy * Business & Policy Newsletters Business & Policy “RAPID CONSOLIDATION” IN ONCOLOGY: NEW DATA Aaron Tallent News 3 Min Read New data show that medical oncologist consolidation rose from 2015 to 2022. “The rate of consolidation seems to be rapid when compared to prior data,” said one author. Prostate Cancer “WHOLE NEW CHALLENGE” IN PROSTATE CANCER? Edwin M. Posadas, MD, FACP, Robert A. Figlin, MD, FACP Podcast Edwin M. Posadas, MD, and Robert A. Figlin, MD discuss how data from the recent EMBARK trial have changed prostate cancer practice and introduced “a whole new challenge.” Melanoma FDA APPROVAL OF TIL “REAL MILESTONE,” EXPERT SAYS Jeffrey Weber, MD, PhD, Robert A. Figlin, MD, FACP Podcast Jeffrey S. Weber, MD, PhD, and Robert A. Figlin, MD, discuss the recent “milestone” approval of a TIL therapy in melanoma and challenges that still remain. Ovarian Cancer NEW OVARIAN CANCER RECOMMENDATIONS RELEASED Leah Lawrence News 4 Min Read ESMO, ESGO, and ESP recently published consensus recommendations for ovarian cancer from a panel of experts across 15 countries, including the United States. Ovarian Cancer FDA OKAYS ADC FOR OVARIAN CANCER Youssef Rddad News 3 Min Read The FDA fully approved mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. TODAY IN ONCOLOGY View All Esophageal Cancer EXACT SCIENCES ADVANCES DEVELOPMENT OF NON-ENDOSCOPIC ONCOGUARD® ESOPHAGUS TEST TO SCREEN FOR ESOPHAGEAL CANCER AND PRE-CANCER source: Yahoo! Finance Lymphoma GENFLEET AND BEIGENE ENTER INTO TRIAL COLLABORATION FOR A POTENTIALLY FIRST-IN-CLASS COMBINATION THERAPY TO INITIATE PHASE IB/II STUDY OF GFH009 (CDK9 INHIBITOR) AND BRUKINSA® (ZANUBRUTINIB) TREATING DIFFUSE LARGE B CELL LYMPHOMA source: Yahoo! Finance Leukemia CANTARGIA REPORTS PROGRESS TOWARDS START OF DOD-SPONSORED CLINICAL TRIAL OF NADUNOLIMAB IN LEUKEMIA source: BioSpace Sarcoma RESULTS OF ADAPTIMMUNE'S SPEARHEAD-1 TRIAL WITH AFAMI-CEL IN ADVANCED SARCOMAS PUBLISHED IN THE LANCET source: Yahoo! Finance EDITORIAL BOARD COMMENTARY View All TED OKON JEFF PATTON, MD STEPHEN SCHLEICHER, MD, MBA DEBRA PATT, MD, PHD, MBA PODCASTS View All Prostate Cancer “WHOLE NEW CHALLENGE” IN PROSTATE CANCER? Edwin M. Posadas, MD, FACP, Robert A. Figlin, MD, FACP Edwin M. Posadas, MD, and Robert A. Figlin, MD discuss how data from the recent EMBARK trial have changed prostate cancer practice and introduced “a whole new challenge.” Melanoma FDA APPROVAL OF TIL “REAL MILESTONE,” EXPERT SAYS Jeffrey Weber, MD, PhD, Robert A. Figlin, MD, FACP Jeffrey S. Weber, MD, PhD, and Robert A. Figlin, MD, discuss the recent “milestone” approval of a TIL therapy in melanoma and challenges that still remain. Urothelial Carcinoma FROM “FAIRYTALE” TO REALITY IN BLADDER CANCER? Robert Dreicer, MD, Robert A. Figlin, MD, FACP Robert Dreicer, MD, and Robert A. Figlin, MD, discuss “paradigm-shifting” data in bladder cancer that mean optimistic outcomes are “not as much of a fairytale.” Breast Cancer BIG CHANGES IN TREATING BREAST CANCER PROGRESSION Ruth M. O’Regan, MD, Robert A. Figlin, MD, FACP Ruth M. O’Regan, MD, and Robert A. Figlin, MD, discuss how newly approved drugs and key data have changed the approach to treating breast cancer progression. MAKING PROGRESS IN SCLC Keep up with the latest developments in SCLC, from experimental agents to new guidelines. IMPROVING OUTCOMES IN BREAST CANCER Learn how recent findings and developments are changing clinical practice in breast cancer. CHALLENGES AND UPDATES IN MYELOMA Keep up with current options, what new regimens may move the bar, and key challenges in the treatment of multiple myeloma. PROGRESS AND UPDATES IN ADVANCED NSCLC Keep up with new treatment modalities and recent developments in the management of locally advanced and metastatic NSCLC. IMPROVING OUTCOMES IN EGFR-MUTATED NSCLC Stay current with the latest information on trials and expert insights. UPDATES IN UROTHELIAL CARCINOMA Learn about the latest approaches for treating patients with urothelial carcinoma and how to choose between them. THE LATEST ONCOLOGY NEWS WAITING IN YOUR INBOX Sign up for free newsletters, including OBR Daily, featuring curated news from major media outlets. Subscribe ONCOLOGY CALCULATORS Tools for oncologists to quickly calculate medical equations and scores, aiding in diagnosis and treatment decisions. View Calculators ALL COVERAGE Prostate Cancer “WHOLE NEW CHALLENGE” IN PROSTATE CANCER? Edwin M. Posadas, MD, FACP, Robert A. Figlin, MD, FACP Podcast Edwin M. Posadas, MD, and Robert A. Figlin, MD discuss how data from the recent EMBARK trial have changed prostate cancer practice and introduced “a whole new challenge.” Prostate Cancer “WHOLE NEW CHALLENGE” IN PROSTATE CANCER? Edwin M. Posadas, MD, FACP, Robert A. Figlin, MD, FACP Podcast Edwin M. Posadas, MD, and Robert A. Figlin, MD discuss how data from the recent EMBARK trial have changed prostate cancer practice and introduced “a whole new challenge.” Endometrial and Uterine Cancers KEY ENDOMETRIAL CANCER DATA FROM SGO 2024 Ursula A. Matulonis, MD Video Ursula A. Matulonis, MD, breaks down results from the pivotal RUBY and NRG GY018 trials, which she says are “very much practice-changing.” Endometrial and Uterine Cancers KEY ENDOMETRIAL CANCER DATA FROM SGO 2024 Ursula A. Matulonis, MD Video Ursula A. Matulonis, MD, breaks down results from the pivotal RUBY and NRG GY018 trials, which she says are “very much practice-changing.” Ovarian Cancer NEW OVARIAN CANCER RECOMMENDATIONS RELEASED Leah Lawrence News 4 Min Read ESMO, ESGO, and ESP recently published consensus recommendations for ovarian cancer from a panel of experts across 15 countries, including the United States. Ovarian Cancer NEW OVARIAN CANCER RECOMMENDATIONS RELEASED Leah Lawrence News 4 Min Read ESMO, ESGO, and ESP recently published consensus recommendations for ovarian cancer from a panel of experts across 15 countries, including the United States. Melanoma FDA APPROVAL OF TIL “REAL MILESTONE,” EXPERT SAYS Jeffrey Weber, MD, PhD, Robert A. Figlin, MD, FACP Podcast Jeffrey S. Weber, MD, PhD, and Robert A. Figlin, MD, discuss the recent “milestone” approval of a TIL therapy in melanoma and challenges that still remain. Melanoma FDA APPROVAL OF TIL “REAL MILESTONE,” EXPERT SAYS Jeffrey Weber, MD, PhD, Robert A. Figlin, MD, FACP Podcast Jeffrey S. Weber, MD, PhD, and Robert A. Figlin, MD, discuss the recent “milestone” approval of a TIL therapy in melanoma and challenges that still remain. Ovarian Cancer FDA OKAYS ADC FOR OVARIAN CANCER Youssef Rddad News 3 Min Read The FDA fully approved mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ovarian Cancer FDA OKAYS ADC FOR OVARIAN CANCER Youssef Rddad News 3 Min Read The FDA fully approved mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Business & Policy “RAPID CONSOLIDATION” IN ONCOLOGY: NEW DATA Aaron Tallent News 3 Min Read New data show that medical oncologist consolidation rose from 2015 to 2022. “The rate of consolidation seems to be rapid when compared to prior data,” said one author. Business & Policy “RAPID CONSOLIDATION” IN ONCOLOGY: NEW DATA Aaron Tallent News 3 Min Read New data show that medical oncologist consolidation rose from 2015 to 2022. “The rate of consolidation seems to be rapid when compared to prior data,” said one author. Endometrial and Uterine Cancers RUCAPARIB MAINTENANCE TIED TO LONGER PFS Leah Lawrence News 3 Min Read Rucaparib maintenance therapy improved PFS in a phase 2 trial in advanced endometrial cancer, but questions remain after an early trial closure. Endometrial and Uterine Cancers RUCAPARIB MAINTENANCE TIED TO LONGER PFS Leah Lawrence News 3 Min Read Rucaparib maintenance therapy improved PFS in a phase 2 trial in advanced endometrial cancer, but questions remain after an early trial closure. Antineoplastics/Chemotherapy FDA UPDATES SAFETY LABEL FOR FLUOROURACIL Youssef Rddad News 2 Min Read The FDA updated safety labeling for fluorouracil injection products. The changes pertain to patients with dihydropyrimidine dehydrogenase deficiency. Antineoplastics/Chemotherapy FDA UPDATES SAFETY LABEL FOR FLUOROURACIL Youssef Rddad News 2 Min Read The FDA updated safety labeling for fluorouracil injection products. The changes pertain to patients with dihydropyrimidine dehydrogenase deficiency. Breast Cancer WHEN TO TREAT NON-TNBC LIKE IT’S TNBC? Erin Frances Cobain, MD, Manali Bhave, MD, Stephanie Graff, MD Video Our panel discusses how data in very low HR-positive, HER2-negative early-stage breast cancer have led to questions about if it should be treated like TNBC. Breast Cancer WHEN TO TREAT NON-TNBC LIKE IT’S TNBC? Erin Frances Cobain, MD, Manali Bhave, MD, Stephanie Graff, MD Video Our panel discusses how data in very low HR-positive, HER2-negative early-stage breast cancer have led to questions about if it should be treated like TNBC. Endometrial and Uterine Cancers NEGATIVE TRIAL MAY INFORM TX IN ENDOMETRIAL CANCER Leah Lawrence News 3 Min Read Lenvatinib plus pembrolizumab did not meet primary endpoints in a phase 3 trial, but some prespecified subgroups may benefit from the combination. Endometrial and Uterine Cancers NEGATIVE TRIAL MAY INFORM TX IN ENDOMETRIAL CANCER Leah Lawrence News 3 Min Read Lenvatinib plus pembrolizumab did not meet primary endpoints in a phase 3 trial, but some prespecified subgroups may benefit from the combination. Blood Cancers FDA APPROVES TKI COMBO FOR CERTAIN ALL Youssef Rddad News 2 Min Read The FDA granted accelerated approval to ponatinib plus chemotherapy for adults with newly diagnosed Philadelphia chromosome-positive ALL. Blood Cancers FDA APPROVES TKI COMBO FOR CERTAIN ALL Youssef Rddad News 2 Min Read The FDA granted accelerated approval to ponatinib plus chemotherapy for adults with newly diagnosed Philadelphia chromosome-positive ALL. Ovarian Cancer MRD DETECTION OPTIONS IN OVARIAN CANCER: NEW DATA Leah Lawrence News 3 Min Read Evaluating MRD with second-look laparoscopy found more patients with ovarian cancer who had MRD than ctDNA assays; ctDNA had greater prognostic discrimination. Ovarian Cancer MRD DETECTION OPTIONS IN OVARIAN CANCER: NEW DATA Leah Lawrence News 3 Min Read Evaluating MRD with second-look laparoscopy found more patients with ovarian cancer who had MRD than ctDNA assays; ctDNA had greater prognostic discrimination. Load More TODAY IN ONCOLOGY View All Esophageal Cancer EXACT SCIENCES ADVANCES DEVELOPMENT OF NON-ENDOSCOPIC ONCOGUARD® ESOPHAGUS TEST TO SCREEN FOR ESOPHAGEAL CANCER AND PRE-CANCER source: Yahoo! Finance Lymphoma GENFLEET AND BEIGENE ENTER INTO TRIAL COLLABORATION FOR A POTENTIALLY FIRST-IN-CLASS COMBINATION THERAPY TO INITIATE PHASE IB/II STUDY OF GFH009 (CDK9 INHIBITOR) AND BRUKINSA® (ZANUBRUTINIB) TREATING DIFFUSE LARGE B CELL LYMPHOMA source: Yahoo! Finance Leukemia CANTARGIA REPORTS PROGRESS TOWARDS START OF DOD-SPONSORED CLINICAL TRIAL OF NADUNOLIMAB IN LEUKEMIA source: BioSpace Sarcoma RESULTS OF ADAPTIMMUNE'S SPEARHEAD-1 TRIAL WITH AFAMI-CEL IN ADVANCED SARCOMAS PUBLISHED IN THE LANCET source: Yahoo! Finance EDITORIAL BOARD COMMENTARY View All TED OKON JEFF PATTON, MD STEPHEN SCHLEICHER, MD, MBA DEBRA PATT, MD, PHD, MBA ONCOLOGY NEWS IN YOUR INBOX… Newsletters FOLLOW US! * Share via twitter * Share via facebook * Share via linkedin * About Us * Contact Us * Editorial Board * Oncology Calculators * Training * Advertise With Us * Sitemap * Our Other Sites * Advertising Policy * Do Not Sell My Info * Privacy Policy * Terms of Use © 2024 HealthCentral LLC. All rights reserved.